Assertio Holdings Inc
ASRT
查看詳細走勢圖
0.720USD
+0.008+1.15%
收盤 12/19, 16:00（美東）報價延遲15分鐘
69.30M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+1.15%
5天
-5.50%
1月
+0.11%
6月
+14.43%
今年開始到現在
-17.35%
1年
-18.73%
查看詳細走勢圖
TradingKey Assertio Holdings Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
Assertio Holdings Inc當前公司基本面數據相對健康，增長潛力很大。當前估值合理，在藥品行業排名105/158位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價2.66。中期看，股價處於下降通道。近一個月，市場表現一般，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Assertio Holdings Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
4
分析師
買入
評級
2.663
目標均價
+241.21%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Assertio Holdings Inc亮點
亮點風險
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
估值低估
公司最新PE估值-2.38，處於3年歷史低位
先鋒集團持倉
明星投資者先鋒集團持倉，最新持倉4.43M股
Assertio Holdings Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Assertio Holdings Inc簡介
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
公司代碼ASRT
公司Assertio Holdings Inc
CEOReisenauer (Mark L)
網址https://www.assertiotx.com/
常見問題
Assertio Holdings Inc(ASRT)的當前股價是多少？
Assertio Holdings Inc(ASRT)的當前股價是 0.720。
Assertio Holdings Inc 的股票代碼是什麼？
Assertio Holdings Inc的股票代碼是ASRT。
Assertio Holdings Inc股票的52週最高點是多少？
Assertio Holdings Inc股票的52週最高點是1.010。
Assertio Holdings Inc股票的52週最低點是多少？
Assertio Holdings Inc股票的52週最低點是0.514。
Assertio Holdings Inc的市值是多少？
Assertio Holdings Inc的市值是69.30M。
Assertio Holdings Inc的淨利潤是多少？
Assertio Holdings Inc的淨利潤為-21.58M。
現在Assertio Holdings Inc(ASRT)的股票是買入、持有還是賣出？
根據分析師評級，Assertio Holdings Inc(ASRT)的總體評級為買入，目標價格為2.663。
Assertio Holdings Inc(ASRT)股票的每股收益（EPS TTM）是多少
Assertio Holdings Inc(ASRT)股票的每股收益（EPS TTM）是-0.302。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
